{"id":55339,"date":"2026-09-14T07:57:34","date_gmt":"2026-09-14T07:57:34","guid":{"rendered":"https:\/\/www.theisn.org\/?p=55339"},"modified":"2026-09-14T08:07:14","modified_gmt":"2026-09-14T08:07:14","slug":"isn-international-expert-forum-report-examines-the-evolving-use-of-complement-inhibitors-in-c3g-and-igan","status":"publish","type":"post","link":"https:\/\/www.theisn.org\/blog\/2026\/09\/14\/isn-international-expert-forum-report-examines-the-evolving-use-of-complement-inhibitors-in-c3g-and-igan\/","title":{"rendered":"ISN\u00a0International\u00a0Expert Forum\u00a0report examines the evolving use of complement inhibitors in\u00a0C3G and\u00a0IgAN\u00a0"},"content":{"rendered":"<p>[vc_row][vc_column][vc_column_text]<i><\/i><span data-contrast=\"auto\">New complement-targeting treatments are changing the therapeutic landscape for C3 glomerulopathy (C3G), primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), and IgA nephropathy (IgAN), raising important questions about how to use them\u00a0in clinical practice. To explore these questions, the ISN convened the\u00a0<\/span><a href=\"https:\/\/www.theisn.org\/in-action\/education\/in-person-meetings\/c3g-igan-budapest-hungary\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">2025 ISN Expert Forum on Complement Therapeutics in C3G &amp; IgAN<\/span><\/a><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.kidney-international.org\/article\/S0085-2538(26)00711-8\/fulltext\" target=\"_blank\" rel=\"noopener\"><b><span data-contrast=\"none\">Read the meeting report in\u00a0<\/span><\/b><b><i><span data-contrast=\"none\">Kidney International<\/span><\/i><\/b><b><span data-contrast=\"none\">\u00ae<\/span><\/b><\/a><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">The forum brought\u00a0together global experts to review current evidence,\u00a0identify\u00a0areas of uncertainty, and consider how complement inhibitors could fit into treatment approaches.\u00a0Key questions include how\u00a0complement\u00a0biomarkers, genetics, and kidney biopsy findings can\u00a0guide therapy, along with\u00a0priorities for future research.<\/span><br \/>\n<span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Explore the ISN\u2019s latest resources on\u00a0rare kidney diseases<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/academy.theisn.org\/products\/iga-nephropathy-curriculum\" target=\"_blank\" rel=\"noopener\"><b><span data-contrast=\"none\">IgA Nephropathy Curriculum<\/span><\/b><\/a><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.theisn.org\/initiatives\/rare-kidney-diseases-toolkit\/\" target=\"_blank\" rel=\"noopener\"><b><span data-contrast=\"none\">ISN Rare Diseases Toolkit<\/span><\/b><\/a><span data-ccp-props=\"{}\">\u00a0<\/span>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text]New complement-targeting treatments are changing the therapeutic landscape for C3 glomerulopathy (C3G), primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), and IgA nephropathy (IgAN), raising important questions about how to use them\u00a0in clinical practice. To explore these questions, the ISN convened the\u00a02025 ISN Expert Forum on Complement Therapeutics in C3G &amp; IgAN.\u00a0 Read the meeting report in\u00a0Kidney International\u00ae\u00a0 [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":47496,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[102,36],"tags":[459,253,203],"class_list":["post-55339","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-education","category-news","tag-c3-glomerulopathy","tag-iga-nephropathy","tag-kidney-disease"],"featured_image_src":{"landsacpe":["https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/05\/ISN_C3GIgAN_May2025_3-900x445.jpg",900,445,true],"list":["https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/05\/ISN_C3GIgAN_May2025_3-366x246.jpg",366,246,true],"medium":["https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/05\/ISN_C3GIgAN_May2025_3-300x200.jpg",300,200,true],"full":["https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/05\/ISN_C3GIgAN_May2025_3.jpg",900,600,false]},"_links":{"self":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/posts\/55339"}],"collection":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/comments?post=55339"}],"version-history":[{"count":3,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/posts\/55339\/revisions"}],"predecessor-version":[{"id":55404,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/posts\/55339\/revisions\/55404"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/media\/47496"}],"wp:attachment":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/media?parent=55339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/categories?post=55339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/tags?post=55339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}